Follow-up characteristics of HCV and non-HCV patients
| Characteristic . | HCV subjects . | Non-HCV subjects . | P . |
|---|---|---|---|
| n | 24 | 288 | — |
| Diastolic blood pressure on follow-up (mmHg) | 84.7 ± 2.3 | 79.6 ± 0.58 | 0.0154 |
| Weighted mean follow-up LDL (mg/dl) | 89.6 ± 14.1 (n = 9) | 124.2 ± 3.54 (n = 148) | 0.0201 |
| Weighted mean follow-up total cholesterol (mg/dl) | 166.8 ± 15.6 (n = 11) | 210.8 ± 4.23 (n = 170) | 0.0108 |
| Weighted mean glycosylated hemoglobin (%) | 9.43 ± 1.1 (n = 10) | 9.94 ± 0.28 (n = 139) | 0.646 |
| Renin angiotensin system inhibitor (ever) | 19/23 (82.6) | 242/270 (89.6) | 0.295 |
| Mean number of blood pressure medications over follow-up | 3.11 ± 0.25 | 3.09 ± 0.09 | 0.959 |
| Follow-up time (months) | 19.5 ± 2.6 | 25.2 ± 1.5 | 0.269 |
| Characteristic . | HCV subjects . | Non-HCV subjects . | P . |
|---|---|---|---|
| n | 24 | 288 | — |
| Diastolic blood pressure on follow-up (mmHg) | 84.7 ± 2.3 | 79.6 ± 0.58 | 0.0154 |
| Weighted mean follow-up LDL (mg/dl) | 89.6 ± 14.1 (n = 9) | 124.2 ± 3.54 (n = 148) | 0.0201 |
| Weighted mean follow-up total cholesterol (mg/dl) | 166.8 ± 15.6 (n = 11) | 210.8 ± 4.23 (n = 170) | 0.0108 |
| Weighted mean glycosylated hemoglobin (%) | 9.43 ± 1.1 (n = 10) | 9.94 ± 0.28 (n = 139) | 0.646 |
| Renin angiotensin system inhibitor (ever) | 19/23 (82.6) | 242/270 (89.6) | 0.295 |
| Mean number of blood pressure medications over follow-up | 3.11 ± 0.25 | 3.09 ± 0.09 | 0.959 |
| Follow-up time (months) | 19.5 ± 2.6 | 25.2 ± 1.5 | 0.269 |
Data are means ± SE or n (%).